PRIMEVAX IMMUNO-ONCOLOGY, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.primevax.com
Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma
Phase 1
Not yet recruiting
- Conditions
- Advanced Melanoma
- Interventions
- Biological: Dengue Virus-1 #45AZ5 (PV-001-DV)Biological: Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- PrimeVax Immuno-Oncology Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03990493
Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma
Phase 1
Not yet recruiting
- Conditions
- Advanced Melanoma
- Interventions
- Biological: Dengue Virus-1 #45AZ5 (PV-001-DV)
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- PrimeVax Immuno-Oncology Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03989895
Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma
Phase 1
Not yet recruiting
- Conditions
- Metastatic Melanoma
- Interventions
- Biological: PV-001-DC
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- PrimeVax Immuno-Oncology Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03803397
© Copyright 2025. All Rights Reserved by MedPath